References
- McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis. 2007;44:e55–56. doi:https://doi.org/10.1086/511685.
- Kredics L, Narendran V, Shobana C, Grou I-H. Filamentous fungal infections of the cornea: a global overview of epidemiology and drug sensitivity. Mycoses. 2015;58:243–260. doi:https://doi.org/10.1111/myc.12306.
- Müller GG, Newton KJ, Castro RSD, et al. Antifungals in eye infections: drugs and routes of administration. Rev Bras Oftalmol. 2013;72(2):132–141. doi:https://doi.org/10.1590/S0034-72802013000200014.
- Saravolatz LD, Johnson LB, Kauffman CA. Voriconazole: anew triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–637.
- Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol. 2010;4:391–405. doi:https://doi.org/10.2147/opth.s6374.
- Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010;146(3):300–304. doi:https://doi.org/10.1001/archdermatol.2009.362.
- Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transplant. 2016;30:1377–1386. doi:https://doi.org/10.1111/ctr.12834.
- Epaulard O, Saint-Raymond C, Villier C, et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect. 2010;16:1362–1364. doi:https://doi.org/10.1111/j.1469-0691.2009.03124.x.
- Palamar M, Egrilmez S, Yilmaz SG, et al. Does topical voriconazole trigger dysplastic changes on the ocular surface? J Chemother. 2015;27(2):111–113. doi:https://doi.org/10.1179/1973947814Y.0000000166.
- Utine CA, Arikan G, Ayhan Z et al. Conjunctival dysplasia after hourly topical antifungal treatment for two months in a case with fusarium keratitis. (Poster presentation) ASCRS- ASOA; May 59, 2017; Los Angeles, USA.
- Arikan G, Karatas E, Lebe B, et al. Topically applied 1% voriconazole induces dysplastic changes on the ocular surface: animal study. Cutan Ocul Toxicol. 2018;37:328–331. doi:https://doi.org/10.1080/15569527.2018.1463237.
- Singh S, Mittal R, Narang P, Mittal V. Ocular surface squamous neoplasia in a setting of fungal keratitis: a rare co occurrence. Int Ophthalmol. 2018. doi:https://doi.org/10.1007/s10792-018-0864-8.
- Denning DW, Griffiths CE. Muco‐cutaneous retinoid‐effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol. 2001;26:648–653. doi:https://doi.org/10.1046/j.1365-2230.2001.00909.x.
- Ona K, Oh DH. Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A. Br J Dermatol. 2015;173(3):751–759. doi:https://doi.org/10.1111/bjd.13862.
- Palamar M, Egrilmez S, Yilmaz SG, et al. Ocular surface squamous neoplasia in a setting of fungal keratitis: a rare co-occurrence. Int Ophthalmol. 2018;2019(39):1209–1210.